180 related articles for article (PubMed ID: 31261289)
21. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic carcinoma surveillance in patients with familial melanoma.
Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
[TBL] [Abstract][Full Text] [Related]
23. FAMMM syndrome: pathogenesis and management.
Czajkowski R; Placek W; Drewa G; Czajkowska A; Uchańska G
Dermatol Surg; 2004 Feb; 30(2 Pt 2):291-6. PubMed ID: 14871223
[TBL] [Abstract][Full Text] [Related]
24. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
26. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
27. Genetics of familial atypical multiple mole-melanoma (FAMMM) syndrome in The Netherlands: how far have we come?
Gruis NA; Van der Velden PA; Bergman W; Frants RR
Bull Cancer; 1998 Jul; 85(7):627-30. PubMed ID: 9752270
[TBL] [Abstract][Full Text] [Related]
28. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
Sargen MR; Merrill SL; Chu EY; Nathanson KL
Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A germline mutations in familial pancreatic cancer.
Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
[TBL] [Abstract][Full Text] [Related]
30. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.
Soura E; Eliades PJ; Shannon K; Stratigos AJ; Tsao H
J Am Acad Dermatol; 2016 Mar; 74(3):395-407; quiz 408-10. PubMed ID: 26892650
[TBL] [Abstract][Full Text] [Related]
31. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.
Cremin C; Howard S; Le L; Karsan A; Schaeffer DF; Renouf D; Schrader KA
Hered Cancer Clin Pract; 2018; 16():7. PubMed ID: 29541281
[TBL] [Abstract][Full Text] [Related]
33. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
[TBL] [Abstract][Full Text] [Related]
34. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
Christodoulou E; Visser M; Potjer TP; van der Stoep N; Rodríguez-Girondo M; van Doorn R; Gruis N
Fam Cancer; 2019 Oct; 18(4):439-444. PubMed ID: 31203567
[TBL] [Abstract][Full Text] [Related]
35. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
36. Head and neck squamous cell carcinoma in FAMMM syndrome.
Vinarsky V; Fine RL; Assaad A; Qian Y; Chabot JA; Su GH; Frucht H
Head Neck; 2009 Nov; 31(11):1524-7. PubMed ID: 19360740
[TBL] [Abstract][Full Text] [Related]
37. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
38. CM-Score: a validated scoring system to predict
Potjer TP; Helgadottir H; Leenheer M; van der Stoep N; Gruis NA; Höiom V; Olsson H; van Doorn R; Vasen HFA; van Asperen CJ; Dekkers OM; Hes FJ;
J Med Genet; 2018 Oct; 55(10):661-668. PubMed ID: 29661971
[TBL] [Abstract][Full Text] [Related]
39. The CDKN2A (p16) gene and human cancer.
Foulkes WD; Flanders TY; Pollock PM; Hayward NK
Mol Med; 1997 Jan; 3(1):5-20. PubMed ID: 9132280
[TBL] [Abstract][Full Text] [Related]
40. Familial pancreatic cancer.
Klein AP; Hruban RH; Brune KA; Petersen GM; Goggins M
Cancer J; 2001; 7(4):266-73. PubMed ID: 11561603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
